论文部分内容阅读
目的观察瑞波西汀治疗脑卒中后抑郁症的疗效与安全性。方法选取卒中后抑郁患者85例,随机分成治疗组51例,对照组34例,治疗4周、8周、16周时观察症状改善适度及药物的不良反应。结果治疗组症状改善明显高于对照组,不良反应轻微。结论瑞波西汀治疗脑卒中后抑郁症疗效确切、不良反应少。
Objective To observe the efficacy and safety of reboxetine in the treatment of post-stroke depression. Methods Eighty-five patients with post-stroke depression were randomly divided into treatment group (n = 51) and control group (n = 34). Moderate symptoms and adverse drug reactions were observed after 4 weeks, 8 weeks and 16 weeks. Results The symptom improvement in the treatment group was significantly higher than that in the control group with slight adverse reactions. Conclusion Reboxetine is effective in treating post-stroke depression with few adverse reactions.